(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
~34,000 sq. ft.
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
~265,000 sq. ft.
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
~22,000 sq. ft.
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
~2,900 m2 (31,000 sq. ft.)
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Chad Briscoe speaks with Dr. David Berkowitz, Director of the Division of Chemistry at
Share This 
Entering the biosimilars market is an enticing prospect for many biopharma companies, offering the potential for reduced development and manufacturing
Share This 
Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions
Share This 
Promising broader patient access to critical medicines, biosimilars offer a more cost-effective alternative therapeutic option compared with originator products. With
Share This 
BioAgilytix adds New VP of Business Development in Europe Hamburg, Germany 01 March 2023 – BioAgilytix, a leading global bioanalytical
Share This 
78,000 Square Feet of Lab and Office Space Added in the First of a Multi-Phase Expansion Durham, NC, October 19,
Share This Entering the biosimilars market is an enticing prospect for many biopharma companies, offering the potential for reduced development and manufacturing
Share This 
3 key challenges facing the biosimilars space in 2023 In 2010, the biopharma industry saw an abrupt patent cliff: a
Share This 
As therapeutic drugs have grown in complexity, so too have the bioanalysis techniques to support these products. Bioanalysis of small molecule
Share This 
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
~34,000 sq. ft.
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
~265,000 sq. ft.
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
~22,000 sq. ft.
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
~2,900 m2 (31,000 sq. ft.)
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Chad Briscoe speaks with Dr. David Berkowitz, Director of the Division of Chemistry at
Share This Entering the biosimilars market is an enticing prospect for many biopharma companies, offering the potential for reduced development and manufacturing
Share This Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions
Share This Promising broader patient access to critical medicines, biosimilars offer a more cost-effective alternative therapeutic option compared with originator products. With
Share This BioAgilytix adds New VP of Business Development in Europe Hamburg, Germany 01 March 2023 – BioAgilytix, a leading global bioanalytical
Share This 78,000 Square Feet of Lab and Office Space Added in the First of a Multi-Phase Expansion Durham, NC, October 19,
Share This Entering the biosimilars market is an enticing prospect for many biopharma companies, offering the potential for reduced development and manufacturing
Share This 3 key challenges facing the biosimilars space in 2023 In 2010, the biopharma industry saw an abrupt patent cliff: a
Share This As therapeutic drugs have grown in complexity, so too have the bioanalysis techniques to support these products. Bioanalysis of small molecule
Share This
Tumor diseases are one the most frequent causes of death in Western industrialized countries. Immune oncological approaches are helping to drive new levels of curative cancer treatment, and could possibly even lead to the eradication of most types of cancer, but development of these tools requires specific and sensitive bioanalytical methods and customized oncology assays.
The clinical landscape for cancer is currently undergoing an exciting shift as the spectrum of available medicines has expanded beyond chemotherapy to a host of new molecularly targeted therapies. While in previous years all cell types were targeted by conventional therapeutics, novel drug options are targeting tumor cells only. Whereas drugs conjugated with specific antibodies (ADC, Antibody-Drug conjugates) bring the tumor-killing agent to its location to eliminate tumor cells only, novel immune oncological therapeutic options take advantage of the immune system to eliminate cancer cells.
The treatment of cancer by immunological tools can be tracked back to the early 1900s when Paul Ehrlich brought up the hypothesis that an intact immune system may protect from most cancers. These ideas led to the concept of immunosurveillance by Burnet and Thomas and immunoediting. With the understanding about the enormous diversity of both the humoral and cellular immune system and the recognition that the immunological players exist in all beings, it was a consequent idea to stimulate the immune system leading to a specific killing of cancer cells.
This molecular and possibly personalized approach may lead to the dusk of generic chemotherapies and to a new level of curative cancer treatment and possibly even to the eradication of most types of cancer.
For more information emphasizing associations of ADA development with pharmacokinetics, efficacy, and safety that are necessary to assess the clinical relevance of immunogenicity.
With the increasing average life span of the population, 14 million new cases of cancer worldwide are diagnosed per year. The following examples are intended to demonstrate the immense power of immune oncological treatment options to address these cases, and are not mentioned to be a comprehensive overview nor a specific prioritization.
The first example are monoclonal antibodies which are directed against cancer-specific antigens, e.g. a monoclonal antibody directed against TYRP1, a protein which is highly expressed in melanocytes and melanoma cells. First results are highly promising that advanced malignant melanoma can be treated.
Another example of a promising immunotherapeutic approach are inhibitors of certain lymphocytes surface marker, e.g. NKTR-214 is a CD122 agonist designed to initiate a rapid proliferation of T- lymphocytes and Natural Killer (NK) cells. In addition, this molecule enhances the expression of PD-1 (programmed cell death protein 1) in these immune cells. Results of a Phase 1 study were recently presented at the 2016 annual meeting of the Society for Immunotherapy of Cancer.
Equally promising is the approach which should be paid attention on is the development of agent that interact with intracellular checkpoints such as PD-1 (programmed cell death protein 1) or LAG-3 (lymphocyte activation gene 3).
And finally, a cellular approach is the use of adoptive cell therapy (ACT) by the generation of chimeric antigen receptor T lymphocytes (CAR-T) which utilize patient’s tumor-infiltrating lymphocytes (TIL) to kill their own tumor cells. Novel molecular tools enable the specific design of these transformed cells. This approach widely opens the doors for personalized medicines.
When it comes to immuno-oncology assessments, a broad range of analytical methods across diverse matrices, including tumor, blood, cells, and DNA/RNA, is necessary to paint the best, most informative picture. Options include the measurement of circulating proteins in the blood using immunoassays; the examination of the cellular component of the blood, including the analysis of circulating tumor cells and/or circulating free DNA via flow cytometry; and tumor gene expression by PCR.
Patient samples are precious and are often subject to limited availability — either in terms of the biopsy material available or blood volume restriction. This necessitates highly sensitive and reproducible assays capable of running small sample volumes, such as the multiplex assays described above. Immunoassays and flow cytometry allow more data to be generated from the smallest amount of sample.
The measurement of gene expression is generally performed by quantitative real-time RCR, and multiplex or singleplex ELISpot analysis is applied for the measurement of specific T- or B cell responses. BioAgilytix has all of these platforms as part of our premier bioanalytical technology suite, including:
Explore insights from BioAgilytix Founder and Board Member, Dr. Afshin Safavi, on some of the innovations taking place in the immuno-oncology field, particularly with CAR T therapies, in one of his latest blog posts.
Immune oncological approaches are exciting tools to curatively treat and possibly eradicate cancer. Several humoral and cellular approaches are followed and are in clinical studies. These novel therapeutic tools require specific and sensitive bioanalytical methods and customized assays. On top of this, a clear and distinct clinical evaluation is needed.
BioAgilytix’s veteran scientists are working alongside leading pharma and biotech companies to advance promising immune oncological approaches and tools, from oncology biomarker development to assays for immunogenicity testing, through expert bioanalysis. Let us help you realize the opportunities available in new molecularly targeted therapies for cancer treatment by leveraging our proven, seasoned scientific support.
2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099
9050 Camino Santa Fe
San Diego, CA 92121
858-652-4600
Fax 858-652-4699
37 Kent St, Woolloongabba
Queensland, 4102, Australia
2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099
9050 Camino Santa Fe
San Diego, CA 92121
858-652-4600
Fax 858-652-4699
37 Kent St,Woolloongabba
Queensland, 4102, Australia
1320 Soldiers Field Road
Boston, MA, 02135
617-456-0700
Fax 617-456-0701
1320 Soldiers Field Road
Boston, MA, 02135
617-456-0700
Fax 617-456-0701
Lademannbogen 10
22339 Hamburg Germany
+49 405267790
85 Commercial Road, Melbourne
Victoria, 3004, Australia
+61 3 9282 2184
Lademannbogen 10
22339 Hamburg Germany
+49 405267790
85 Commercial Road, Melbourne
Victoria, 3004, Australia
+61 3 9282 2184
